International Multicentric Observational Study to Characterize Subpopulations of Patients
To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication
| Condition(s) | Autism Spectrum Disorder |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication |
| Who can participate | Inclusion Criteria: * Participants previously diagnosed with ASD (DSM-5) * Available well-documented health records within the first 2 years of life * Participants must have a parent or reliable caregiver who agrees to provide information about the participant * Participants willing and consenting or assenting to participate. Exclusion Criteria: * Episode of fever (i.e. ≥100.5 °F or ≥ 38 °C) or clinically significant illness without fever (as judged by the investigator), within 10 days before any study assessment. * If the investigator assesses any unwillingness or any medical condition that may prevent the subject from completing this study. |
| Ages | 12 Years to 65 Years |
| Sex | All |
| Lead sponsor | Stalicla SA |
| Locations | Phoenix, Arizona, United States; Sherman Oaks, California, United States; Miami, Florida, United States; Miami Lakes, Florida, United States; Chicago, Illinois, United States; Columbia, Missouri, United States (+15 more sites) |
| Start date | 2022-10-13 |
| NCT ID | NCT05590715 |
| Official listing | https://clinicaltrials.gov/study/NCT05590715 |